Dr. Yusuf Yilmaz
My Social Links

Dr. Yusuf Yilmaz

Professor
Marmara University, Turkiye

Highest Degree
M.D. in Medicine from Istanbul University, Turkiye

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Nonalcoholic Steatohepatitis
62%
Noninvasive Biomarkers
90%
Hepatocyte Apoptosis
75%
Liver Disease
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Ozturk, K., T. Dogan, S. Celikkanat, A. Ozen and H. Demirci et al., 2018. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 30: 411-417.
    Direct Link  |  
  2. Yilmaz, Y. and F. Eren, 2017. Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. Turk. J. Gastroenterol., 28: 327-328.
    Direct Link  |  
  3. Uygun, A., K. Ozturk, H. Demirci, A. Oztuna and F. Eren et al., 2017. The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study. Eur. J. Gastroenterol. Hepatol., 29: 441-447.
    CrossRef  |  Direct Link  |  
  4. Kaymakoglu, S., I. Koksal, F. Tabak, U.S. Akarca and A. Akbulut et al., 2017. Recommendation for treatment of hepatitis C virus infection. Turk. J. Gastroenterol., 28: 94-100.
    Direct Link  |  
  5. Ozguven, S., T. Ones, Y. Yilmaz, H.T. Turoglu and N. Imeryuz, 2016. The role of active brown adipose tissue in human metabolism. Eur. J. Nucl. Med. Mol. Imaging, 43: 355-361.
    CrossRef  |  Direct Link  |  
  6. Kaya, E., D. Demir, Y.O. Alahdab and Y. Yilmaz, 2016. Prevalence of hepatic steatosis in apparently healthy medical students: A transient elastography study on the basis of a controlled attenuation parameter. Eur. J. Gastroenterol. Hepatol., 28: 1264-1267.
    CrossRef  |  Direct Link  |  
  7. Ergelen, R., Y. Yilmaz, R. Asedov, C. Celikel and H. Akin et al., 2016. Comparison of doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis. Abdom. Radiol., 41: 1505-1510.
  8. Akyuz, U., Y. Yilmaz, A.T. Ince, B. Kaya and C. Pata, 2016. Diagnostic role of colon capsule endoscopy in patients with optimal colon cleaning. Gastroenterol. Res. Pract., Vol. 2016. 10.1155/2016/2738208.
    CrossRef  |  Direct Link  |  
  9. Sunbul, M., T. Kivrak, E. Durmus, H. Akin and Y. Aydin et al., 2015. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc. Ther., 33: 294-299.
    CrossRef  |  Direct Link  |  
  10. Subasi, C.F., U.E. Aykut and Y. Yilmaz, 2015. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 27: 137-141.
    CrossRef  |  Direct Link  |  
  11. Ozturk, O., Y. Colak, E. Senates, Y. Yilmaz and C. Ulasoglu et al., 2015. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World J. Gastroenterol., 21: 8096-8102.
    CrossRef  |  Direct Link  |  
  12. Ergelen, R., U. Akyuz, Y. Aydin, F. Eren and Y. Yilmaz, 2015. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 27: 667-671.
    CrossRef  |  Direct Link  |  
  13. Dincses, E. and Y. Yilmaz, 2015. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 27: 1149-1153.
    CrossRef  |  Direct Link  |  
  14. Akyuz, U., A. Yesil and Y. Yilmaz, 2015. Characterization of lean patients with nonalcoholic fatty liver disease: Potential role of high hemoglobin levels. Scand. J. Gastroenterol., 50: 341-346.
    CrossRef  |  Direct Link  |  
  15. Yonal, O., F. Eren, Y. Yilmaz, O. Atug and H.H. Over, 2014. No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. Turk. J. Gastroenterol., 25: 639-643.
  16. Yilmaz, Y., T. Ayyildiz, H. Akin, Y. Colak and O. Ozturk et al., 2014. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver, 8: 313-317.
    CrossRef  |  Direct Link  |  
  17. Yilmaz, Y., E. Senates, A. Yesil, R. Ergelen and Y. Colak, 2014. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J. Diabetes Complications, 28: 328-331.
    CrossRef  |  Direct Link  |  
  18. Yilmaz, Y., A. Yesil, F. Gerin, R. Ergelen, H. Akin, C.A. Celikel and N. Imeryuz, 2014. Detection of hepatic steatosis using the controlled attenuation parameter: A comparative study with liver biopsy. Scand. J. Gastroenterol., 49: 611-616.
    CrossRef  |  Direct Link  |  
  19. Yilmaz, Y. and Z.M. Younossi, 2014. Obesity-associated nonalcoholic fatty liver disease. Clin. Liver Dis., 18: 19-31.
    CrossRef  |  Direct Link  |  
  20. Yilmaz, Y. and F. Eren, 2014. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol., 26: 1292-1295.
  21. Yesil, A. and Y. Yilmaz, 2014. Letter: Gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease-authors' reply. Aliment. Pharmacol. Ther., 39: 1442-1442.
  22. Sunbul, M., M. Agirbasli, E. Durmus, T. Kivrak and H. Akin et al., 2014. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis, 237: 490-493.
    CrossRef  |  Direct Link  |  
  23. Musso, G., R. Gambino, J.H. Tabibian, M. Ekstedt and S. Kechagias et al., 2014. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med., Vol. 11. 10.1371/journal.pmed.1001680.
    CrossRef  |  Direct Link  |  
  24. Emanuele, E., P. Minoretti, F. Sanchis-Gomar, H. Pareja-Galeano, Y. Yilmaz, N. Garatachea and A. Lucia, 2014. Can enhanced autophagy be associated with human longevity? Serum levels of the autophagy biomarker beclin-1 are increased in healthy centenarians. Rejuvenation Res., 17: 518-524.
    CrossRef  |  Direct Link  |  
  25. Colak, Y., A. Yesil, H.H. Mutlu, O.T. Caklili and C. Ulasoglu et al., 2014. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J. Gastrointestin. Liver Dis., 23: 311-319.
    Direct Link  |  
  26. Aykut, U.E., U. Akyuz, A. Yesil, F. Eren and F. Gerin et al., 2014. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand. J. Gastroenterol., 49: 1343-1348.
    CrossRef  |  Direct Link  |  
  27. Yilmaz, Y., Y. Colak, R. Kurt, E. Senates and F. Eren, 2013. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: From bedside to bench and back. Tumori, 99: 10-16.
  28. Yilmaz, Y., R. Ergelen, H. Akin and N. Imeryuz, 2013. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur. J. Gastroenterol. Hepatol., 25: 1330-1334.
  29. Yilmaz, Y., O. Ozturk, Y.O. Alahdab, E. Senates and Y. Colak et al., 2013. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive Liver Dis., 45: 58-62.
    CrossRef  |  
  30. Yilmaz, Y., 2013. Letter: Diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 37: 283-283.
  31. Yilmaz, Y., 2013. Biomarkers for early detection of non-alcoholic steatohepatitis: Implications for drug development and clinical trials. Curr. Drug Targets, 14: 1357-1366.
    Direct Link  |  
  32. Yesil, A. and Y. Yilmaz, 2013. Coffee consumption, the metabolic syndrome and non‐alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 38: 1038-1044.
    CrossRef  |  Direct Link  |  
  33. Purnak, T. and Y. Yilmaz, 2013. Liver disease and malnutrition. Best Pract. Res. Clin. Gastroenterol., 27: 619-629.
    CrossRef  |  Direct Link  |  
  34. Colak, Y., E. Senates, A. Yesil, Y. Yilmaz and O. Ozturk et al., 2013. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 43: 100-107.
    CrossRef  |  Direct Link  |  
  35. Yilmaz, Y., O. Yonal, O. Deyneli, C.A. Celikel, C. Kalayci and D.G. Duman, 2012. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol. Belg., 75: 240-244.
    Direct Link  |  
  36. Yilmaz, Y., F. Eren, Y. Colak, E. Senates, C.A. Celikel and N. Imeryuz, 2012. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand. J. Gastroenterol., 47: 1488-1493.
    CrossRef  |  Direct Link  |  
  37. Yilmaz, Y., E. Senates, T. Ayyildiz, Y. Colak and I. Tuncer et al., 2012. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur. J. Clin. Invest., 42: 411-418.
    CrossRef  |  Direct Link  |  
  38. Yilmaz, Y., 2012. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clin. Chim. Acta, 413: 1190-1193.
    CrossRef  |  Direct Link  |  
  39. Yilmaz, Y., 2012. NAFLD in the absence of metabolic syndrome: Different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin. Liver Dis., 32: 14-21.
  40. Yilmaz, Y., 2012. Is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions? Aliment. Pharmacol. Ther., 36: 815-823.
    CrossRef  |  Direct Link  |  
  41. Yilmaz, Y., 2012. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome? World J. Hepatol., 4: 332-334.
  42. Yilmaz, Y., 2012. Fructose in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 35: 1135-1144.
  43. Yilmaz, Y., 2012. Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis. Scand. J. Gastroenterol., 47: 489-490.
    CrossRef  |  Direct Link  |  
  44. Yilmaz, Y., 2012. Review article: Non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Aliment. Pharmacol. Ther., 36: 345-352.
  45. Yilmaz, Y. and R. Kurt, 2012. Is M65 really better than M30 as a biomarker of hepatic fibrosis? Hepatology, 55: 654-654.
  46. Yilmaz, Y. and F. Eren, 2012. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin. Chim. Acta, 414: 154-157.
    CrossRef  |  Direct Link  |  
  47. Kurt, R. and Y. Yilmaz, 2012. Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease. Clin. Biochem., 45: 515-515.
  48. Eren, F., R. Kurt, F. Ermis, O. Atug, N. Imeryuz and Y. Yilmaz, 2012. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin. Biochem., 45: 655-658.
    CrossRef  |  Direct Link  |  
  49. Colak, Y., I. Tuncer, E. Senates, O. Ozturk, L. Doganay and Y. Yilmaz, 2012. Nonalcoholic fatty liver disease: A nutritional approach. Metab. Syndr. Relat. Disord., 10: 161-166.
  50. Colak, Y., E. Senates, O. Ozturk, Y. Yilmaz and E. Zemheri et al., 2012. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: Association with liver histology. Eur. J. Gastroenterol. Hepatol., 24: 255-261.
  51. Colak, Y., E. Senates, E. Coskunpinar, Y.M. Oltulu and E. Zemheri et al., 2012. Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Dis. Markers, 33: 77-83.
    PubMed  |  
  52. Atasoy, B.M., O. Yonal, B. Demirel, F. Dane and Y. Yilmaz et al., 2012. The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy. Eur. Arch. Oto-Rhino-Laryngol., 269: 275-282.
    CrossRef  |  Direct Link  |  
  53. Alahdab, Y.O., F. Eren, A. Giral, F. Gunduz and A.E. Kedrah et al., 2012. Preliminary evidence of an association between the functional c‐kit rs6554199 polymorphism and achalasia in a Turkish population. Neurogastroenterol. Motility, 24: 27-30.
    CrossRef  |  Direct Link  |  
  54. Yilmaz, Y., T. Ones, T. Purnak, S. Ozguven and R. Kurt et al., 2011. Association between the presence of brown adipose tissue and non‐alcoholic fatty liver disease in adult humans. Aliment. Pharmacol. Ther., 34: 318-323.
    CrossRef  |  Direct Link  |  
  55. Yilmaz, Y., R. Kurt, A. Gurdal, Y.O. Alahdab and O. Yonal et al., 2011. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis, 217: 125-129.
    CrossRef  |  Direct Link  |  
  56. Yilmaz, Y., R. Kurt and F. Eren, 2011. Multimarker strategies for detecting NASH and NASH- related fibrosis: Promises and caveats. Obes. Surg., 21: 1316-1317.
  57. Yilmaz, Y., O. Yonal, R. Kurt, Y.O. Alahdab and O. Ozdogan et al., 2011. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch. Med. Res., 42: 38-43.
    CrossRef  |  Direct Link  |  
  58. Yilmaz, Y., O. Yonal, R. Kurt, Y.O. Alahdab and F. Eren et al., 2011. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand. J. Gastroenterol., 46: 91-97.
    CrossRef  |  Direct Link  |  
  59. Yilmaz, Y., O. Yonal, R. Kurt, M. Bayrak, B. Aktas and O. Ozdogan, 2011. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease. Hepat. Mon., 11: 103-107.
    Direct Link  |  
  60. Yilmaz, Y., O. Yonal, F. Eren, R. Kurt and C.A. Celikel et al., 2011. Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. Clin. Chem. Lab. Med., 49: 93-97.
    CrossRef  |  Direct Link  |  
  61. Yilmaz, Y., O. Yonal, F. Eren, O. Atug and H.O. Hamzaoglu, 2011. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity. J. Crohn's Colitis, 5: 402-406.
    CrossRef  |  Direct Link  |  
  62. Yilmaz, Y., F. Eren, T. Ayyildiz, Y. Colak and R. Kurt et al., 2011. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clin. Chim. Acta, 412: 2296-2299.
    CrossRef  |  Direct Link  |  
  63. Yilmaz, Y., F. Eren, R. Kurt, O. Yonal and Z. Polat et al., 2011. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clin. Biochem., 44: 955-958.
    CrossRef  |  Direct Link  |  
  64. Yilmaz, Y., F. Eren, O. Yonal, Z. Polat and M. Bacha et al., 2011. Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dis. Markers, 31: 205-210.
    CrossRef  |  Direct Link  |  
  65. Yilmaz, Y., 2011. Cytokeratins in hepatitis. Clin. Chim. Acta, 412: 2031-2036.
  66. Yilmaz, Y. and F. Eren, 2011. Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?" Metabolism, 60: e2-e2.
  67. Yilmaz, Y. and E. Ulukaya, 2011. Toward a biochemical diagnosis of NASH: Insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. Curr. Med. Chem., 18: 725-732.
    CrossRef  |  PubMed  |  
  68. Ulukaya, E., C. Acilan, F. Ari, E. Ikitimur and Y. Yilmaz, 2011. A glance at the methods for the detection of apoptosis qualitatively and quantitatively: An update of literature. Turk. J. Biochem., 36: 261-269.
  69. Ulukaya, E., C. Acilan and Y. Yilmaz, 2011. Apoptosis: Why and how does it occur in biology? Cell Biochem. Funct., 29: 468-480.
    CrossRef  |  PubMed  |  Direct Link  |  
  70. Senates, E., Y. Yilmaz, Y. Colak, O. Ozturk and M.E. Altunoz et al., 2011. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metab. Syndr. Relat. Disord., 9: 287-290.
    CrossRef  |  Direct Link  |  
  71. Colak, Y., E. Senates, O. Ozturk, Y. Yilmaz and E. Coskunpinar et al., 2011. Plasma fibrinogen-like protein 2 levels in patients with non-alcoholic fatty liver disease. Hepato-gastroenterology, 58: 2087-2090.
    PubMed  |  
  72. Bekar, O., Y. Yilmaz and M. Gulten, 2011. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J. Med. Food, 14: 344-347.
    CrossRef  |  Direct Link  |  
  73. Ari, E., Y. Yilmaz, A.E. Kedrah, Y. Alahdab and F. Cakalagaoglu et al., 2011. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy. Am. J. Nephrol., 33: 269-276.
    CrossRef  |  Direct Link  |  
  74. Aktas, B., Y. Yilmaz, F. Eren, O. Yonal and R. Kurt et al., 2011. Serum levels of vaspin, obestatin and apelin-36 in patients with nonalcoholic fatty liver disease. Metab.-Clin. Exp., 60: 544-549.
    CrossRef  |  Direct Link  |  
  75. Yilmaz, Y., Y.O. Alahdab, O. Yonal, R. Kurt and C.A. Celikel et al., 2010. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Metabolism, 59: 1327-1330.
    CrossRef  |  PubMed  |  Direct Link  |  
  76. Yilmaz, Y., Y.O. Alahdab, O. Yonal, N. Imeryuz and C. Kalayci, 2010. Reply: Microalbuminuria and nonalcoholic fatty liver disease. Metabolism, 59: E5-E5.
  77. Yilmaz, Y., R. Kurt, O. Yonal, N. Polat and C.A. Celikel et al., 2010. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Atherosclerosis, 211: 182-186.
    CrossRef  |  PubMed  |  Direct Link  |  
  78. Yilmaz, Y., R. Kurt and C. Kalayci, 2010. Liver enzymes and cardiovascular outcomes: A new research agenda. Hepatology, 52: 2242-2242.
    CrossRef  |  Direct Link  |  
  79. Yilmaz, Y., R. Kurt and C. Kalayci, 2010. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: Zooming in on cytokeratin 18 fragments. Biomarkers Med., 4: 743-745.
    CrossRef  |  Direct Link  |  
  80. Yilmaz, Y., O. Yonal, R. Kurt, F. Ari and A.Y. Oral et al., 2010. Serum fetuin A/α 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Ann. Clin. Biochem., 47: 549-553.
    CrossRef  |  Direct Link  |  
  81. Yilmaz, Y., O. Yonal, R. Kurt, A.Y. Oral and F. Eren et al., 2010. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scandınavıan J. Clin. Lab. Invest., 70: 541-546.
    CrossRef  |  PubMed  |  Direct Link  |  
  82. Yilmaz, Y., O. Yonal, R. Kurt and E. Avsar, 2010. Cigarette smoking is not associated with specific histological features or severity of nonalcoholic fatty liver disease. Hepatology, 52: 391-391.
  83. Yilmaz, Y., F. Eren, O. Yonal, R. Kurt and B. Aktas et al., 2010. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur. J. Clin. Invest., 40: 887-892.
    CrossRef  |  Direct Link  |  
  84. Yilmaz, Y., 2010. The AGEs-RAGE axis and nonalcoholic steatohepatitis: The evidence mounts. J. Gastroenterol., 45: 782-783.
    CrossRef  |  PubMed  |  Direct Link  |  
  85. Yilmaz, Y., 2010. Liver function tests: Association with cardiovascular outcomes. World J. Hepatol., 2: 143-145.
  86. Yilmaz, Y. and E. Ulukaya, 2010. Molecular signatures of NAFLD: The present and future. Hepatology, 51: 1866-1866.
  87. Olmez, O.F., S. Gurel and Y. Yilmaz, 2010. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. Eur. J. Gastroenterol. Hepatol., 22: 461-465.
    CrossRef  |  PubMed  |  Direct Link  |  
  88. Kurt, R., Y. Yilmaz, F. Ermis, S.K. Besisik and N. Polat, 2010. Folic acid and vitamin B12 supplementation improves coronary flow reserve in elderly subjects with vitamin B12 deficiency. Arch. Med. Res., 41: 369-372.
    CrossRef  |  
  89. Gul, O.O., E. Tuncel, Y. Yilmaz, E. Ulukaya and C.B. Gul et al., 2010. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes patients. Metab. Clin. Exp., 59: 64-69.
    CrossRef  |  PubMed  |  Direct Link  |  
  90. Eren, F., Y. Yilmaz, S. Kose, F.T. Ozdemir and O. Yonal et al., 2010. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin. Chim. Acta, 411: 2029-2032.
    CrossRef  |  
  91. Yilmaz, Y., Y.O. Alahdab, O. Ozdogan and E. Dolar, 2009. NAFLD and microalbuminuria in nondiabetic patients: Role of insulin resistance. Intern. Med. J., 39: 709-710.
  92. Yilmaz, Y., O. Yonal and N. Imeryuz, 2009. Metformin, hepatitis C and insulin resistance: Sufficient evidence? Hepatology, 50: 2054-2055.
  93. Yilmaz, Y., O. Atug, O. Yonal, D. Duman, O. Ozdogan, N. Imeryuz and C. Kalayci, 2009. Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease. Med. Sci. Monit., 15: HY1-HY5.
    PubMed  |  Direct Link  |  
  94. Yilmaz, Y., E. Ulukaya, O.O. Gul, M. Arabul and C.B. Gul et al., 2009. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin. Biochem., 42: 802-807.
    CrossRef  |  Direct Link  |  
  95. Yilmaz, Y., E. Ulukaya, O. Atug and E. Dolar, 2009. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance. Eur. J. Gastroenterol. Hepatol., 21: 1247-1251.
    CrossRef  |  PubMed  |  Direct Link  |  
  96. Yilmaz, Y., E. Ulukaya and E. Dolar, 2009. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. Hepatology, 49: 1056-1057.
    CrossRef  |  Direct Link  |  
  97. Yilmaz, Y., E. Ulukaya and E. Dolar, 2009. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. Hepatology, 49: 697-697.
    CrossRef  |  PubMed  |  Direct Link  |  
  98. Yilmaz, Y., E. Dolar, E. Ulukaya, S. Akgoz and M. Keskin et al., 2009. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med. Sci. Monit., 15: CR189-CR193.
    Direct Link  |  
  99. Yilmaz, Y., E. Dolar and E. Ulukaya, 2009. Commentary on the study of Vos et al. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr., 49: 371-371.
    PubMed  |  
  100. Yilmaz, Y., E. Armagan, O.F. Olmez, M. Esen, N. Alkis and E. Dolar, 2009. Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report. Hum. Exp. Toxicol., 28: 63-65.
    CrossRef  |  PubMed  |  Direct Link  |  
  101. Yilmaz, Y., B. Baran, N.B. Seniz and E. Dolar, 2009. Familial Mediterranean fever coexisting with celiac disease: Is there a link with long-term colchicine treatment? J. Gastrointestin. Liver Dis., 18: 119-120.
    PubMed  |  
  102. Yilmaz, Y., A.E. Kedrah and O. Ozdogan, 2009. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J. Gastroenterol., 15: 4387-4391.
    CrossRef  |  PubMed  |  Direct Link  |  
  103. Yilmaz, Y., 2009. “Defragmenting” the noninvasive diagnosis of nonalcoholic steatohepatitis: Hopes from cytokeratin‐18. Hepatology, 50: 990-991.
    CrossRef  |  PubMed  |  Direct Link  |  
  104. Yilmaz, Y., 2009. Systematic review: Caspase‐cleaved fragments of cytokeratin 18-the promises and challenges of a biomarker for chronic liver disease. Aliment. Pharmacol. Ther., 30: 1103-1109.
    CrossRef  |  PubMed  |  Direct Link  |  
  105. Yilmaz, Y. and O. Ozdogan, 2009. Liver disease as a risk factor for cognitive decline and dementia: An under‐recognized issue. Hepatology, 49: 698-698.
    CrossRef  |  PubMed  |  Direct Link  |  
  106. Yilmaz, Y. and E. Dolar, 2009. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations? World J. Gastroenterol., 15: 4346-4347.
  107. Ulukaya, E., Y. Yilmaz, S. Moshkovskii, M. Vlaslova, M. Pyatnitskiy, A. Ozlen and E. Dolar, 2009. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scandinavian J. Gastroenterol., 44: 1471-1476.
    Direct Link  |  
  108. Tiftikci, A., O. Atug, Y. Yilmaz, F. Eren and F.T. Ozdemir et al., 2009. Serum levels of adipokines in patients with chronic HCV infection: Relationship with steatosis and fibrosis. Arch. Med. Res., 40: 294-298.
    CrossRef  |  PubMed  |  Direct Link  |  
  109. Senturk, T., A. Aydinlar, Y. Yilmaz, A.Y. Oral, O. Ozdabakoglu and E. Ulukaya, 2009. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease. Coron Artery Dis., 20: 494-498.
    CrossRef  |  PubMed  |  
  110. Keskin, M., E. Dolar, M. Dirican, M. Kiyici and Y. Yilmaz et al., 2009. Baseline and salt‐stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity. Intern. Med. J., 39: 243-248.
    CrossRef  |  Direct Link  |  
  111. Fazlioglu, M., T. Senturk, E. Kumbay, A.A. Kaderli and Y. Yilmaz et al., 2009. Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid. Atherosclerosis, 202: 200-204.
    CrossRef  |  PubMed  |  Direct Link  |  
  112. Atug, O., H. Akin, Y. Yilmaz, M. Sari and N. Tozun, 2009. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C. J. Gastrointestin. Liver Dis., 18: 256-256.
    PubMed  |  
  113. Ari, E., Y. Yilmaz, A. Gul, Y.O. Alahdab and A.E. Kedrah et al., 2009. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes and low platelet count. Am. J. Reprod. Immunol., 62: 238-242.
    CrossRef  |  Direct Link  |  
  114. Arabul, M., M. Gullulu, Y. Yilmaz, M.A. Eren and B. Baran et al., 2009. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients. Med. Sci. Monit., 15: CR583-CR587.
    PubMed  |  Direct Link  |  
  115. Akgullu, C., Y. Yilmaz, E. Yucel, A.A. Kaderli, E. Kumbay and A. Aydinlar, 2009. Coronary artery anomalies in patients with syndrome X. Anadolu Kardiyol. Derg., 9: 69-69.
    PubMed  |  Direct Link  |  
  116. Yilmaz, Y., E. Ulukaya and E. Dolar, 2008. A “biomarker biopsy” for the diagnosis of NASH: Promises from CK-18 fragments. Obes. Surg., 18: 1507-1508.
    CrossRef  |  PubMed  |  Direct Link  |  
  117. Yilmaz, Y., C.B. Gul, M. Arabul and M.A. Eren, 2008. Helicobacter pylori: A role in schizophrenia? Med. Sci. Monit., 14: HY13-HY16.
    PubMed  |  Direct Link  |  
  118. Yilmaz, Y., 2008. Psychopathology in the context of obesity: The adiponectin hypothesis. Med. Hypotheses., 70: 902-903.
    CrossRef  |  PubMed  |  Direct Link  |  
  119. Yilmaz, Y., 2008. Apical ballooning syndrome: A metabolic form of cardiomyopathy? Med. Sci. Monit., 14: HY9-HY12.
    PubMed  |  Direct Link  |  
  120. Yilmaz, Y. and E. Dolar, 2008. Concomitant colitis in a patient with Behcet’s disease. J. Gastrointestin. Liver Dis., 17: 481-483.
    PubMed  |  
  121. Gul, C.B., M. Gullulu, B. Oral, A. Aydinlar and O. Oz et al., 2008. Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention? Clin. Biochem., 41: 544-547.
    CrossRef  |  PubMed  |  Direct Link  |  
  122. Falcone, C., D. Geroldi, M.P. Buzzi, E. Emanuele and Y. Yilmaz et al., 2008. The −374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch. Med. Res., 39: 320-325.
    CrossRef  |  PubMed  |  Direct Link  |  
  123. Catalano, M., A. Cortelazzo, Y. Yilmaz, E. Perilli, G. Carzaniga and E. Emanuele, 2008. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. Clin. Chim. Acta, 387: 109-112.
    CrossRef  |  PubMed  |  Direct Link  |  
  124. Catalano, M., A. Cortelazzo, R. Santi, L. Contino and M. Demicheli et al., 2008. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble rage (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin. Biochem., 41: 981-985.
    CrossRef  |  PubMed  |  Direct Link  |  
  125. Baran, B., Y. Yilmaz, O. Algin, M. Keskin, M. Kiyici, G. Kocamaz and E. Dolar, 2008. Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia. Blood Coagul. Fibrinolysis, 19: 243-246.
    CrossRef  |  PubMed  |  Direct Link  |  
  126. Armagan, E., Y. Yilmaz, O.F. Olmez, G. Simsek and C.B. Gul, 2008. Predictive value of the modified early warning score in a Turkish emergency department. Eur. J. Emerg. Med., 15: 338-340.
    CrossRef  |  PubMed  |  Direct Link  |  
  127. Arabul, M., M. Gullulu, Y. Yilmaz, I. Akdag, S. Kahvecioglu, M.A. Eren and K. Dilek, 2008. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin. Biochem., 41: 1055-1058.
    CrossRef  |  PubMed  |  Direct Link  |  
  128. Akgullu, C., B. Ozdemir, Y. Yilmaz, A.R. Kazazoglu and A. Aydinlar, 2008. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. Acta Cardiol., 63: 467-471.
    CrossRef  |  PubMed  |  Direct Link  |  
  129. Akdag, I., Y. Yilmaz, S. Kahvecioglu, N. Bolca, I. Ercan, A. Ersoy and M. Gullulu, 2008. Clinical value of the malnutrition-inflammation-atherosclerosis (MIA) syndrome for long term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study. Nephron. Clin. Pract., 108: c99-c105.
    PubMed  |  
  130. Yilmaz, Y., E. Dolar, E. Ulukaya, S. Akgoz and M. Keskin et al., 2007. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J. Gastroenterol., 13: 837-844.
    CrossRef  |  PubMed  |  
  131. Torun, S., E. Dolar, Y. Yilmaz, M. Keskin and M. Kiyici et al., 2007. Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients. World J. Gastroenterol., 13: 6027-6030.
    CrossRef  |  PubMed  |  Direct Link  |  
  132. Oral, A.Y., E. Ulukaya and Y. Yılmaz, 2007. VEGF, VEGF-receptors and lung cancer. Adv. Mol. Med., 3: 15-21.
    CrossRef  |  Direct Link  |  
  133. Akkaya, O., M. Kiyici, Y. Yilmaz, E. Ulukaya and O. Yerci, 2007. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J. Gastroenterol., 13: 5481-5485.
    PubMed  |  Direct Link  |